ClinicalTrials.gg
CompletedNCT03394989Updated Aug 13, 2020

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

A Phase 3 interventional study of Fluticasone propionate/salmeterol 100/50 µg and Placebo in Bronchial Asthma, sponsored by Cipla Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Cipla Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,366
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
59th of 1,353
1,366 · median 100
Started
2018
with 67 others
Phase 3
254 of 1,695
14 open now
Registered
1,210th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 59th largest by enrollment of the 1,353 interventional ones that give a count, is one of 68 that started in 2018, is one of 254 in phase 3, and was the 1,210th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in adult patients with asthma.

Read the detailed description

This study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in terms of FEV1 measured at different time-points in adult patients with asthma.

03

Conditions studied

  • Bronchial Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have signed form before initiation of any study related procedure.
  2. Male or female patients who are ≥18 years of age at the time informed consent is obtained.
  3. Documented diagnosis of asthma as defined by the National Asthma Education and Prevention Program (NAEPP) and diagnosed at least 12 weeks prior to screening.
  4. Patients with pre-bronchodilator (FEV1) of 40% to 85% (both inclusive) of the predicted normal value at the Screening Visit V2.
  5. Patients who demonstrated an increase of ≥15% of FEV1 within 15 30 minutes following administration of albuterol at Screening Visit V2
  6. Patients who are stable on current asthma treatment for at least 4 weeks prior to Screening Visit V1.
  7. Patients who are able to discontinue their current asthma medications (if any) and any other prohibited medications throughout the study, per the protocol list of prohibited medications during study participation (see Section 6.3.2).
  8. Patients who are able to replace their current short-acting beta 2 agonist (SABA) inhaler with the study provided albuterol inhaler to be used as rescue medicine (as needed) throughout the study. Patients who are able to withhold SABAs for at least 6 hours prior to lung function assessments on study visits.
  9. Patient who are non-smokers or ex-smokers; and have had ≤10 pack years
  10. Patients who have not inhaled tobacco or consumed other tobacco containing products have not inhaled vaping products, drugs of abuse, or inhaled marijuana for at least 12 months prior to screening.
  11. Women of (WOCBP) must not be lactating or pregnant at screening, as documented by a negative screening pregnancy test
  12. Women of childbearing potential must commit to consistent and correct use of an acceptable method of (at the investigator's discretion) throughout the study.

Exclusion criteria

Exclusion criteria:

  1. History of life-threatening asthma defined as an asthma episode(s) that required intubation and/or was associated with hypercapnic, respiratory arrest, or hypoxic seizures, asthma related syncopal episode(s) within the past one year.
  2. History of any asthma-related hospitalizations within the past one year.
  3. Any asthma exacerbation requiring emergency room (ER) visits or systemic (including oral) within 2 months prior to signing the consent.
  4. Evidence or history of disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia (prolonged as judged by the investigator). In addition, historical or current evidence of significant hematologic, hepatic neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
  5. Patients with uncontrolled allergic rhinitis.
  6. Clinical visual evidence of oral candidiasis.
  7. History of any adverse reaction; known to any sympathomimetic drug
  8. Use of medication(s) with potential to affect the course of asthma or to interact with sympathomimetic amines throughout the study period.
  9. Recent viral or bacterial infection or infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 4 weeks of screening.
  10. Patients, who in the opinion of the investigator, significantly abuse alcohol or drugs will be excluded.
  11. Use of systemic (including oral) corticosteroids within 4 weeks or intramuscular depot corticosteroid treatment 90 days prior to screening for any reason other than asthma (see exclusion criteria #3 above).
  12. Patients taking any medications within 4 weeks prior to screening and during the study.
  13. Factors (e.g., infirmity, disability, geographic location) that the investigator felt would likely limit the patients' compliance with the study protocol or scheduled clinic visits.
  14. Use of any drug (approved or unapproved) within 30 days
  15. Study participation by clinical investigator site employees and/or their immediate relatives.
  16. Patients who are unable to produce valid and reproducible spirometry per American Thoracic Society/European Respiratory Society (ATS/ERS) standards at the screening visit or unable to use the electronic diary (e diary).
  17. Patients unable to use the inhalation powder device adequately.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,366 participants (actual)

Study arms

  • Experimental
    Test

    Fluticasone propionate/salmeterol 100/50 µg

    Drug: Fluticasone propionate/salmeterol 100/50 µg

  • Active comparator
    Comparator

    Fluticasone propionate/salmeterol 100/50 µg

    Drug: Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT

  • Other
    Placebo

    Test Placebo

    Other: Placebo

Interventions

  • DrugFluticasone propionate/salmeterol 100/50 µg

    Test Arm: Dry powder inhaler

  • OtherPlacebo

    Placebo

  • DrugAdvair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT

    Comparator Arm: Dry powder inhaler

06

What researchers measure

Primary outcomes

  1. Area under the serial Force Expiration volume1 from time 0 to 12 hours (AUC0-12 hours)

    Area under the serial Force Expiration volume1 from time 0 to 12 hours (AUC0-12 hours) on the first day of the treatment

    Time frame: one day

07

Study locations

1 site
  • Combined Research Orlando
    Orlando, Florida 32807, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Dec 2019, 13 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 13 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2017
First posted
Jan 9, 2018
StartActual
Oct 17, 2018
Primary completionActual
Dec 3, 2019
CompletionActual
Mar 31, 2020
Last update
Aug 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03394989
Lead sponsor
Cipla Ltd.
Responsible party
Sponsor
First posted
Jan 9, 2018
Start date
Oct 17, 2018
Primary completion
Dec 3, 2019
Completion
Mar 31, 2020
Last update
Aug 13, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion